{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:08:27Z","timestamp":1779023307627,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,17]]},"DOI":"10.7759\/cureus.109019","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:38:50Z","timestamp":1779021530000},"source":"Crossref","is-referenced-by-count":0,"title":["Sequential Clinical Changes Following Autologous Mesenchymal Stem Cell Therapy in a Patient With Concurrent Huntington's Disease and Ankylosing Spondylitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Ruslana","family":"Gurskaia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross CA","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98. 10.1016\/S1474-4422(10)70245-3","journal-title":"Lancet Neurol"},{"key":"ref2","unstructured":"INGREZZA. (2023). Accessed. 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209241s026lbl.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli A","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008, 8:726-36. 10.1038\/nri2395","journal-title":"Nat Rev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau J","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018, 22:824-33. 10.1016\/j.stem.2018.05.004","journal-title":"Cell Stem Cell"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro T","year":"2016","unstructured":"Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016, 25:829-48. 10.3727\/096368915X689622","journal-title":"Cell Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al.. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68:777-83. 10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency","volume":"11","year":"1996","unstructured":"Unified Huntington's Disease Rating Scale. reliability and consistency. Mov Disord. 1996, 11:136-42. 10.1002\/mds.870110204","journal-title":"Mov Disord"},{"key":"ref9","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994, 21:2281-5.","journal-title":"J Rheumatol"},{"key":"ref10","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21:2286-91.","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici M","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, et al.. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8:315-7. 10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14670\/HH-24.107","article-title":"Bone marrow stromal cells for spinal cord repair: a challenge for contemporary neurobiology","volume":"24","author":"Vaquero J","year":"2009","unstructured":"Vaquero J, Zurita M. Bone marrow stromal cells for spinal cord repair: a challenge for contemporary neurobiology. Histol Histopathol. 2009, 24:107-16. 10.14670\/HH-24.107","journal-title":"Histol Histopathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"Bonelli RM","year":"2006","unstructured":"Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006, 12:2701-20. 10.2174\/138161206777698693","journal-title":"Curr Pharm Des"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487331-sequential-clinical-changes-following-autologous-mesenchymal-stem-cell-therapy-in-a-patient-with-concurrent-huntingtons-disease-and-ankylosing-spondylitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:38:52Z","timestamp":1779021532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487331-sequential-clinical-changes-following-autologous-mesenchymal-stem-cell-therapy-in-a-patient-with-concurrent-huntingtons-disease-and-ankylosing-spondylitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.109019","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,17]]}}}